For dividend-focused investors seeking both safety and stability, this large-cap healthcare stock remains a standout choice. With a low beta of just 0.48 — signaling much lower price volatility compared to the broader market — and a forward dividend yield of 3.35%, this company offers a rare blend of income generation and risk mitigation. Operating at the heart of the healthcare and life sciences industry, it develops prescription therapies and advanced surgical technologies, serving global healthcare providers with a diversified revenue stream across essential medical needs. Backed by a fortress balance sheet, including a 0.4x net leverage ratio, it has maintained uninterrupted dividend increases for 50+ consecutive years, making it one of the most reliable sources of passive income.
The healthcare sector is benefiting from long-term demographic tailwinds, rising global demand for innovative treatments, and increased investment in medical technology. This company is capitalizing on those trends with new therapy launches and surgical technology innovations while navigating challenges like competitive pressures in medical devices and biologic erosion in its pharmaceutical portfolio. Management’s proactive investment strategy and product pipeline expansions signal that future growth remains firmly on track, even as some legacy revenue headwinds weigh on near-term results. Risk-averse investors looking for a resilient stock with clear strategic growth drivers and defensive characteristics will find compelling reasons to dig deeper.
Since its most recent earnings call on April 15, 2025, shares have climbed 4.2%, demonstrating renewed investor confidence. Meanwhile, sales estimates have edged up 1.03%, EBITDA estimates have improved 1.27%, and EPS estimates have risen 0.45%, suggesting analysts are increasingly optimistic about future profitability.
To see why this healthcare giant continues to earn its place in the Safe Dividend Portfolio — and whether it deserves a place in your own — be sure to read the full analysis.
